Xeraya Capital — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
OncoMyx TherapeuticsinDec 2021
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesDelos CapitalKorea Investment PartnersLumira Ventures+1 more
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.